within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX52_Venetoclax;

model Venetoclax
  extends Pharmacolibrary.Drugs.ATC.L.L01XX52;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01XX52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Venetoclax is a selective inhibitor of B-cell lymphoma-2 (BCL-2) protein, used primarily for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It promotes apoptosis of cancer cells by inhibiting BCL-2, a protein that helps cancer cells survive. Venetoclax is an approved drug for hematological malignancies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on adults with hematologic malignancies receiving single or multiple oral doses. The values mainly reflect patients with normal hepatic and renal function.</p><h4>References</h4><ol><li><p>Roberts, AW, et al., &amp; Seymour, JF (2016). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>The New England journal of medicine</i> 374(4) 311–322. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1513257&quot;>10.1056/NEJMoa1513257</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26639348/&quot;>https://pubmed.ncbi.nlm.nih.gov/26639348</a></p></li><li><p>Salem, AH, &amp; Menon, RM (2024). Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. <i>Clinical and translational science</i> 17(5) e13807–None. DOI:<a href=&quot;https://doi.org/10.1111/cts.13807&quot;>10.1111/cts.13807</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38778732/&quot;>https://pubmed.ncbi.nlm.nih.gov/38778732</a></p></li><li><p>Agarwal, SK, et al., &amp; Salem, AH (2017). Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. <i>Clinical therapeutics</i> 39(2) 359–367. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2017.01.003&quot;>10.1016/j.clinthera.2017.01.003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28161120/&quot;>https://pubmed.ncbi.nlm.nih.gov/28161120</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Venetoclax;
